Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (782)	4/24/2007 5:19:21 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 824

Speaking of legumes, here is another data point on CD200: ajp.amjpathol.org In particular, The CD200-CD200R pathway plays a critical role in attenuating EAE and reducing inflammation-mediated damage in the CNS. Strategies that up-regulate the expression of CD200 in the CNS or molecules that ligate the CD200R may be relevant as neuroprotective strategies in multiple sclerosis. The ALXN mAb blocks CD200/CD200R, which leads to enhancement of immune response, so this is the flip side of the story. PB

To: kenhott who wrote (782)	4/27/2007 9:37:14 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 824

Be glad to. Haven't read it yet. Skimmed quickly. Engineered human lines, transplanted into a sophisticated mouse model. Highly irrelevant, fascinating model that can teach a ton. So, I don't have a good memory, given exposure to agonists. People should remind me, when I don't get back to them. I barely remembered this one, and I very much appreciate being asked to summarize it. Not nearly as rude as I appear to be. Remind me, please. Back to the track meet. Great 110m race this afternoon. Son lost to arch rival by 0.06 seconds, closest yet.